FIRST AMENDMENT TO THE COLLABORATION AGREEMENT

        THIS FIRST AMENDMENT TO THE COLLABORATION AGREEMENT (the "Amendment") is entered into as of June 30, 2000 (the "Amendment Date"), by and between RIGEL PHARMACEUTICALS, INC., a Delaware corporation ("Rigel") with its offices at 240 East Grand Avenue, South San Francisco, CA 94080, and JANSSEN PHARMACEUTICA N.V., a Belgian corporation ("Janssen") with offices at Turnhoutseweg 30, 2340 Beerse, Belgium (Rigel and Janssen individually referred to as "Party", and collectively as "Parties"). This Amendment is an amendment of the original Collaboration Agreement (the "Agreement") entered into as of December 4, 1998 (the "Effective Date"), by and between the Parties.

        The Parties hereby agree to the following amendments to the Agreement:

        1.    As used in this Amendment:

        2.    Section 2.7(d) of the Agreement ("RMC Functions and Powers") shall be amended to read as follows:

        3.    Under Article 3 of the Agreement ("Research Activities; Revisions"), New Section 3.2© is added as follows:

        4.    Section 6.2 of the Agreement ("Financial Support") shall be amended to read as follows:

        IN WITNESS WHEREOF, the Parties hereto have duly executed this Amendment.

RIGEL PHARMACEUTICALS, INC. JANSSEN PHARMACEUTICA, N.V.

By:

 

/s/  JAMES M GOWER      

 

By:

 

/s/  ANNE FABSENNE WEZTSEN      
Name: James M. Gower Name: Anne Fabsenne Weztsen
Title: President and CEO Title: Senior Director
       

 

 

 

 

By:

 

/s/  DIDIER DE CHAFFOY DE COURCELLES      
    Name: Didier de Chaffoy de Courcelles
    Title: Senior Vice-President,
Discovery Research Worldwide

Source: OneCLE Business Contracts.